ADDENDUM - MEDICAL AND HEALTH CONSEQUENCES OF DRUG ABUSE PROGRAMANNOUNCEMENT (PA-96-010) NIH Guide, Volume 26, Number 5, February 14, 1997 P.T. 34 Keywords: Drugs/Drug Abuse 0765034 Epidemiology Etiology National Institute on Drug Abuse PURPOSE This notice is an addendum to program announcement Medical and Health Consequences of Drug Abuse, PA-96-010, published in the NIH Guide, Vol. 24, No. 42, December 8, 1995. The purpose of this addendum is to encourage research on the occurrence and distribution of drug-abuse related morbidity and mortality in both clinical and large population-based epidemiologic studies, as well as clinical studies of the natural history and etiology of morbidity and mortality associated with drug abuse. This includes surveillance studies, such as incidence and prevalence studies in general populations or subpopulations of drug users, as well as biomedical studies within clinical settings, such as primary care or drug treatment programs. RESEARCH OBJECTIVES Systematic efforts are needed to respond to a lack of current information on the morbidity and mortality associated with patterns of drug abuse. Data on morbidity and mortality are needed on the infectious, neurologic, psychiatric, obstetric/gynecological, neonatal, and other pathophysiological consequences of drug abuse. The need for new data arises in part from multiple dynamic factors which influence drug abuse related morbidity and mortality. Such factors include: 1) the availability of new drugs and drug combinations, 2) routes of drug administration, 3) hygienic practices, 4) drug-related violent behaviors, 5) access, utilization, and availability of care, 6) emergence of new pathogens and resistance patterns, and 7) drug abuse patterns related to cultural, immigration and travel patterns. Types of currently funded studies appropriate for supplementation include: 1) Cohort studies of drug users which are examining the natural history of HIV disease in both seronegatives and seropositives; 2) Large population-based studies of the treatment careers or natural history of drug abuse 3) Health services research studies of access, availability, utilization, and effectiveness of medical and mental health services to drug users; 4) Community outreach and intervention studies which identify populations of active drug users otherwise difficult to access through drug treatment or primary care; and 5) Community epidemiology studies focused on identifying emerging patterns of drug abuse and/or HIV/AIDS. SPECIAL REQUIREMENTS BUDGET/ADMINISTRATIVE ISSUES There are no set-aside funds for this effort. Funding for the supplements is subject to availability of research program grant funds. Competing supplements are provided for expansion of a project's scope or the research protocol. These are treated as new applications for purposes of the review requirements and competition for funds, and are reviewed in accordance with NIH standard procedures, i.e., peer review/council review. Competing renewal supplement requests must be submitted in accordance with standard receipt dates; March 1, July 1, and November 1. Administrative supplements are provided to cover unanticipated cost increases that are associated with achieving the objectives within the original scope of a project, and include cost increases that result from making modifications in the scope of a project in order to take advantage of opportunities that would increase the value of the project consistent with its originally approved objectives and purposes. Administrative supplemental funding is generally limited to 25 percent of the Council-approved direct costs of the project or $100,000, whichever is less. These applications undergo program, grants management, and budget review within NIDA and may be submitted for the remainder of FY 1997, but no later than August 1, 1997. INQUIRIES Inquiries concerning this announcement are encouraged. The opportunity to clarify any issue or questions from potential applicants are welcome. For programmatic issues, contact: Jag Khalsa, Ph.D. Division of Clinical and Services Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-08 Rockville, MD 20857 Telephone: (301) 443-1801 FAX: (301) 594-6566 Email: jk98p@nih.gov For fiscal matters, contact: Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8A-54 Rockville, MD 20857 Telephone: (301) 443-6710 Email: gf6s@nih.gov .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |